These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 15964668

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC, Johansson BE.
    Virology; 2005 Sep 01; 339(2):273-80. PubMed ID: 15996702
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees.
    Kilbourne ED, Cerini CP, Khan MW, Mitchell JW, Ogra PL.
    J Immunol; 1987 May 01; 138(9):3010-3. PubMed ID: 3571981
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Difficulties in standardizing the neuraminidase content of influenza vaccines.
    Gérentes L, Kessler N, Aymard M.
    Dev Biol Stand; 1999 May 01; 98():189-96; discussion 197. PubMed ID: 10494973
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N, Li W, Li Y, Liu S, Sui Y, Qu Z, Wang Y, Du Y, Xu B.
    Vaccine; 2008 Jun 02; 26(23):2912-8. PubMed ID: 18448208
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ, Lee CW, Sylte M, Suarez DL.
    Vaccine; 2009 Oct 19; 27(44):6247-60. PubMed ID: 19686695
    [Abstract] [Full Text] [Related]

  • 19. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
    Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G.
    Vaccine; 2005 Dec 30; 23(50):5751-9. PubMed ID: 16143432
    [Abstract] [Full Text] [Related]

  • 20. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
    Johansson BE, Pokorny BA, Tiso VA.
    Vaccine; 2002 Feb 22; 20(11-12):1670-4. PubMed ID: 11858877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.